NEW YORK (GenomEWeb News) - CombiMatrix said today that it will provide chromosomal microarray analysis-based testing for miscarriage analysis for ProPath, a pathology services provider.

The agreement enables ProPath to add a new product to its suite of women's health diagnostics, one that "can play a significant role in a comprehensive miscarriage analysis," according to Kenneth Youens, ProPath's women's health director. He added that "the accuracy, clinical utility and quick turnaround times of CMA testing makes it a superior first tier testing option."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.